185 related articles for article (PubMed ID: 20404855)
1. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis.
Strout MP; Seropian S; Berliner N
Nat Rev Clin Oncol; 2010 Jul; 7(7):415-20. PubMed ID: 20404855
[TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab treatment for hemophagocytic lymphohistiocytosis.
Machaczka M; Vaktnäs J; Chiang SC; Bryceson YT
Nat Rev Clin Oncol; 2010 Oct; 7(10):. PubMed ID: 21080519
[No Abstract] [Full Text] [Related]
3. Importance of allogeneic T-cells for disease control after stem cell transplantation for high-risk Langerhans cell histiocytosis.
Steiner M; Matthes-Martin S; Attarbaschi A; Lawitschka A; Minkov M; Mittheisz E; Fritsch G; Lion T; Zoubek A; Gadner H
Haematologica; 2007 Jan; 92(1):e3-4. PubMed ID: 17405740
[TBL] [Abstract][Full Text] [Related]
4. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.
Faulkner RD; Craddock C; Byrne JL; Mahendra P; Haynes AP; Prentice HG; Potter M; Pagliuca A; Ho A; Devereux S; McQuaker G; Mufti G; Yin JL; Russell NH
Blood; 2004 Jan; 103(2):428-34. PubMed ID: 12969983
[TBL] [Abstract][Full Text] [Related]
5. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.
Morris E; Thomson K; Craddock C; Mahendra P; Milligan D; Cook G; Smith GM; Parker A; Schey S; Chopra R; Hatton C; Tighe J; Hunter A; Peggs K; Linch D; Goldstone A; Mackinnon S
Blood; 2004 Dec; 104(13):3865-71. PubMed ID: 15304395
[TBL] [Abstract][Full Text] [Related]
6. The Role of Hematopoietic Stem Cell Transplantation in Treatment of Hemophagocytic Lymphohistiocytosis.
Nikiforow S
Hematol Oncol Clin North Am; 2015 Oct; 29(5):943-59. PubMed ID: 26461153
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma.
Chanan-Khan A; Islam T; Alam A; Miller KC; Gibbs J; Barcos M; Czuczman MS; Paplham P; Hahn T; McCarthy P
Leuk Lymphoma; 2004 Aug; 45(8):1673-5. PubMed ID: 15370223
[TBL] [Abstract][Full Text] [Related]
8. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.
Kröger N; Shaw B; Iacobelli S; Zabelina T; Peggs K; Shimoni A; Nagler A; Binder T; Eiermann T; Madrigal A; Schwerdtfeger R; Kiehl M; Sayer HG; Beyer J; Bornhäuser M; Ayuk F; Zander AR; Marks DI;
Br J Haematol; 2005 Jun; 129(5):631-43. PubMed ID: 15916686
[TBL] [Abstract][Full Text] [Related]
9. Fever, shock, and pancytopenia in a patient treated with alemtuzumab.
Bauer MP; van Burgel ND; Marijt WA; van Dissel JT; von dem Borne PA
Clin Infect Dis; 2009 Nov; 49(10):1540; 1616-7. PubMed ID: 19857167
[No Abstract] [Full Text] [Related]
10. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
Chakraverty R; Orti G; Roughton M; Shen J; Fielding A; Kottaridis P; Milligan D; Collin M; Crawley C; Johnson P; Clark A; Parker A; Bloor A; Pettengell R; Snowden J; Pettitt A; Clark R; Hale G; Peggs K; Thomson K; Morris E; Mackinnon S
Blood; 2010 Oct; 116(16):3080-8. PubMed ID: 20587785
[TBL] [Abstract][Full Text] [Related]
11. Hemophagocytic lymphohistiocytosis with a hemizygous PRF1 c.674G>A mutation.
Xin X; Wang N; Zhang Y
Am J Med Sci; 2023 Nov; 366(5):387-394. PubMed ID: 37467895
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
[TBL] [Abstract][Full Text] [Related]
13. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study.
Delgado J; Thomson K; Russell N; Ewing J; Stewart W; Cook G; Devereux S; Lovell R; Chopra R; Marks DI; Mackinnon S; Milligan DW;
Blood; 2006 Feb; 107(4):1724-30. PubMed ID: 16239425
[TBL] [Abstract][Full Text] [Related]
14. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
Pérez-Simón JA; Kottaridis PD; Martino R; Craddock C; Caballero D; Chopra R; García-Conde J; Milligan DW; Schey S; Urbano-Ispizua A; Parker A; Leon A; Yong K; Sureda A; Hunter A; Sierra J; Goldstone AH; Linch DC; San Miguel JF; Mackinnon S;
Blood; 2002 Nov; 100(9):3121-7. PubMed ID: 12384408
[TBL] [Abstract][Full Text] [Related]
15. Emerging role of Alemtuzumab in renal and renal-pancreas transplantation.
Sureshkumar KK; Hussain SM; Zimmer BW; Marcus RJ
Expert Opin Biol Ther; 2008 Oct; 8(10):1605-25. PubMed ID: 18774927
[TBL] [Abstract][Full Text] [Related]
16. Unusual acute lupus hemophagocytic syndrome - a test of diagnostic criteria: a case report.
Wijetunga WMUA; Satarasinghe RL; Dayananda BM; Darshani GK
J Med Case Rep; 2017 Jul; 11(1):185. PubMed ID: 28683778
[TBL] [Abstract][Full Text] [Related]
17. Rediscovering alemtuzumab: current and emerging therapeutic roles.
Gribben JG; Hallek M
Br J Haematol; 2009 Mar; 144(6):818-31. PubMed ID: 19183194
[TBL] [Abstract][Full Text] [Related]
18. Remission induction using alemtuzumab can permit chemotherapy-refractory chronic lymphocytic leukemia (CLL) patients to undergo allogeneic stem cell transplantation.
Knauf W; Rieger K; Blau W; Hegenbart U; Von Gruenhagen U; Niederwieser D; Thiel E
Leuk Lymphoma; 2004 Dec; 45(12):2455-8. PubMed ID: 15621759
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients.
Kirsch BM; Haidinger M; Zeyda M; Böhmig GA; Tombinsky J; Mühlbacher F; Watschinger B; Hörl WH; Säemann MD
Transpl Immunol; 2006 Nov; 16(3-4):254-7. PubMed ID: 17138063
[TBL] [Abstract][Full Text] [Related]
20. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.
Dodero A; Carrabba M; Milani R; Rizzo E; Raganato A; Montefusco V; Farina L; Milanesi M; Longoni P; Carlo-Stella C; Corradini P
Exp Hematol; 2005 Aug; 33(8):920-7. PubMed ID: 16038785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
